Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
-
-
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
-
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
-
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
-
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
-
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
-
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
-
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
-
Novavax and Government of Canada finalize advance purchase agreement for COVID-19 vaccine
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
-
Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine
On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant…
-
Novavax finalized agreement with Commonwealth of Australia for 51 million doses of COVID-19 vaccine
On Jan. 7, 2021, Novavax announced that it had executed an Advance Purchase Agreement with the Commonwealth of…
-
Additional DOD locations selected to support COVID-19 vaccine clinical trials
On Dec. 29, 2020, the U.S. Department of Defense (DOD) announced that the Womack Army Medical Center was…
-
UNMC participated in COVID-19 vaccine study, planned to enroll 1,000
On Dec. 29, 2020, University of Nebraska Medical Center (UNMC) and Nebraska Medicine announced participation in a clinical…
-
Novavax initiated PREVENT-19 pivotal phase 3 efficacy trial of COVID-19 vaccine in the U.S. and Mexico
On Dec. 28, 2020, Novavax announced initiation of PREVENT-19, its pivotal Phase 3 study in the U.S. and…
-
Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccine
On Dec. 16, 2020, Novavax announced an Advance Purchase Agreement with the government of New Zealand for the…
-
Novavax announced COVID-19 vaccine clinical development progress
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
-
COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
-
Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine
On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…
-
Novavax announced facility expansion to support global vaccine development
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
-
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
-
Novavax initiated phase 3 efficacy trial of COVID-19 vaccine in the UK
On Sept. 24, 2020, Novavax announced that it had initiated its first Phase 3 study to evaluate the…
-
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
-
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
-
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
-
Novavax and Canada reached agreement to acquire Novavax COVID-19 vaccine
On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada…
-
Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine
On Aug. 24, 2020, Novavax announced that the first volunteers were enrolled in the Phase 2 portion of…
-
Catalent signed agreement with AstraZeneca to expand manufacturing support for COVID-19 vaccine AZD1222
On Aug. 24, 2020, Catalent announced that it had contracted to provide drug substance manufacturing to AstraZeneca for…
-
Novavax initiated efficacy trial of COVID-19 vaccine in South Africa
On Aug. 17, 2020, Novavax announced the beginning of a Phase 2b clinical trial in South Africa to…
